BR0014138A - Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo - Google Patents

Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo

Info

Publication number
BR0014138A
BR0014138A BR0014138-0A BR0014138A BR0014138A BR 0014138 A BR0014138 A BR 0014138A BR 0014138 A BR0014138 A BR 0014138A BR 0014138 A BR0014138 A BR 0014138A
Authority
BR
Brazil
Prior art keywords
antigen
replication
individual
immune response
adenoviral vector
Prior art date
Application number
BR0014138-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of BR0014138A publication Critical patent/BR0014138A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0014138-0A 1999-09-21 2000-09-20 Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo BR0014138A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
BR0014138A true BR0014138A (pt) 2002-05-21

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014138-0A BR0014138A (pt) 1999-09-21 2000-09-20 Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Ｂｃｇワクチンとその利用
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
JP5646851B2 (ja) * 2006-11-17 2014-12-24 ジェネトロニクス，インコーポレイティド エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
CA2699465C (en) * 2007-09-14 2017-11-28 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX380483B (es) * 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Also Published As

Publication number Publication date
WO2001021201A3 (en) 2001-10-18
DK1214416T3 (da) 2005-08-29
DE60020136D1 (de) 2005-06-16
DE60020136T2 (de) 2006-02-23
CA2384806A1 (en) 2001-03-29
JP2003509470A (ja) 2003-03-11
EP1612269A1 (en) 2006-01-04
EP1214416A2 (en) 2002-06-19
AU7302400A (en) 2001-04-24
EP1214416B1 (en) 2005-05-11
ATE295421T1 (de) 2005-05-15
AU762894B2 (en) 2003-07-10
CN1391609A (zh) 2003-01-15
GB9922361D0 (en) 1999-11-24
ES2241653T3 (es) 2005-11-01
WO2001021201A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
EP1363660A4 (en) HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
DK1349926T3 (da) Komplementerende cellelinier
GB2384709A (en) Vaccination method
WO2008011609A3 (en) Compositions and methods for vaccinating against hsv-2
DK0979284T4 (da) Reagenser til vaccination, som fremkalder en CD8 T-celleimmunreaktion
BR9811475A (pt) Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
BR0308755A (pt) Misturas de tintura de azo reativas à fibra, preparação e uso das mesmas
JP2003509470A5 (enExample)
NO984244L (no) Vaksinesammensetninger og fremgangsmÕter som er nyttige i Õ indusere immunbeskyttelse mot artritogene peptider som er involvert i patogenese av reumatoid artritt
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
AU8467201A (en) Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
Föhring et al. Adenovirus type 12 specific cell surface antigen in transformed cells is a product of the E1b early region
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
DE69937258D1 (de) Genetische impstoffe mit adjuvans
BR0013574A (pt) Antìgeno vacina de moraxella
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
BR9810046A (pt) Sequência de nucleotìdeos, vetor de expressão, célula hospedeira, proteìna de esperma de mamìfero, proteìna de esperma recombinante, proteìna 4, 1 e/ou 6,7 de esperma, composição farmacêutica, e, vacina contraceptiva
林裕 Timing and role of p53 gene mutation in the recurrence of glioma
Tilemans Paracrine control of the development of anterior pituitary cells in the rat.
EP1457211A4 (en) RECOMBINANT VACCINIA VIRUS VACCINE

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.